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Abstract As the prevalence of children on renal replace-
ment therapy (RRT) increases world wide and such therapy
comprises at least 2% of any national dialysis or transplant
programme, it is essential that paediatric nephrologists are
abletoadvise families onthepossibleoutcomefortheirchild
on dialysis. Most children start dialysis with the expectation
that successful renal transplantation is an achievable goal
and will provide the best survival and quality of life.
However, some will require long-term dialysis or may return
intermittently to dialysis during the course of their chronic
kidney disease (CKD). This article reviews the available
outcome data for children on chronic dialysis as well as
extrapolating datafromthelargeradultdialysisexperienceto
inform our paediatric practice. The multiple factors that may
influence outcome, and, particularly, those that can poten-
tially be modified, are discussed.
Keywords Dialysis.Children.Long-termoutcome.
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Mortality in children on dialysis
Survival data for paediatric patients on chronic dialysis from
both national registries and single-centre studies can provide
useful information. In this paper we have compiled data from
large national registries, including the United States Renal
Data System (USRDS), a compulsory registration system,
which includes children ≤ 19 years; the North American
PediatricRenalTrialsandCollaborative Studies(NAPRTCS),
which allows voluntary data reporting and includes children
≤ 21 years; the United Network for Organ Sharing (UNOS),
which collects data on all patients registered for renal
transplantation in the USA; the European Renal Associa-
tion–European Dialysis and Transplant Association (ERA–
EDTA), a voluntary organization, which coordinates a
national European registry for all patients; the Australia and
New Zealand Dialysis and Transplant Association (ANZ-
DATA), which is a comprehensive, compulsory database
including children up to 20 years of age; and other national
registries, including the United Kingdom Renal Registry, the
National Dutch Registry, and the Italian Registry, and present
the key points.
USRDS data for 2006 [1] report an adjusted mortality
rate for dialysis patients (age 0–19 years) who started
treatment between 1995 and 1999 of 56.5/1,000 patient
years at risk. In their most recent report, NAPRTCS
reviewed the survival data of 2,781 patients aged 0–21 years
on long-term dialysis without a history of previous
transplantation and whose index dialysis course was the
first for the patient [2]. The patient survival rates were 95%,
90.1% and 85.7% at 1 year, 2 years, and 3 years,
respectively (censored for transplantation or if lost to
follow-up) [2]. Offering the longest longitudinal follow-up
period over four decades, ANZDATA reports on the long-
term survival rates of 1,634 children under 20 years of age
who started renal replacement therapy (RRT) between 1963
and 2002 and can, therefore, uniquely offer 20-year
survival data [3]. At 10 years, survival rate was 79%, and,
at 20 years, it was 66% [3], Fig. 1.
Of the causes of death specified, cardiopulmonary
disease was the reason cited most often, at 21.5% overall
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attributes 41% of deaths to cardiovascular disease and 21%
to infection [4]. Similarly, ANZDATA reports that the most
common cause of death of those on dialysis was cardiovas-
cular disease (45%), with the second most common being
infection (21%) [3]. Cardiovascular disease accounted for
57% of deaths in children on haemodialysis and 43% of
those on peritoneal dialysis, compared with 30% in those
with a functioning transplant in whom malignancy was
responsible for 14% of deaths [3].
Factors influencing outcome
Overall mortality in dialysis patients compared with healthy
children and those with transplants
Dialysis in children carries a significantly higher mortality
rate than that for the age-adjusted population. In 2002 a
Dutch Registry cohort study determined the mortality rate
of 381 children with the onset of end-stage renal disease
(ESRD) aged 0–14 years between 1972 and 1992 [4]. The
overall mortality rate was 1.57/100 patient years for RRT
patients, while the mortality rate standardized for age
(which compares a specific age group in a certain year
divided by the expected mortality in that age group in the
same year) was 31 [4]. Similarly, in the larger ANZDATA
report, mortality rates were 30-times higher than for
children without chronic kidney disease (CKD) [3].
Dialysis treatment was also associated with a mortality risk
more than four-times higher than for children who had
received a transplant [3] .T h eU N O Sd a t af r o m2 0 0 2r e p o r t
a mortality rate of 21/1,000 patient years for dialysis patients
and 2/1,000 patient years for transplant recipients [5].
Era of dialysis
ANZDATA reports a substantial improvement in the long-
term survival rates of children and adolescents with CKD
stage 5, with a mortality rate of 11 per 100 patient years
between 1963 and 1972 and 1.8 per 100 patient years in those
who started dialysis after 1993 [3]. The Dutch cohort reports
a similar improvement, with survival rates of 81% and 79%
at 5 years and 10 years for children on dialysis from 1972 to
1981 compared to 89% and 85%, respectively, in the 1982–
1991 cohort, including those with a functioning graft [4].
However, the USRDS reports only a marginal improve-
ment in survival during the 1990s, with 88.5% of patients
who began dialysis between 1990 and 1995 surviving,
compared to 89.2% survival for those who started dialysis
from 1995–1999 [1]. The continued improvement in
survival rates with time may be underestimated, as younger
children and those with significant non-renal co-morbidity
are taken onto dialysis programmes.
Age at start of dialysis
All registries report a significantly higher mortality rate in
infants starting dialysis. ANZDATA clearly identified younger
age at the start as a risk factor, with a 5-year survival, if under
1 year at the start of RRT, of 73% compared to 86% for the
whole population and a fourfold increased risk of death
compared to children aged 15–19years,Fig.1 [3]. NAPRTCS
report the highest mortality rate in children less than a year
old at the start of dialysis, with survival rates of 83.2%,
74.3% and 66.4% at 1 year, 2 years and 3 years [2]. By
further analysing the NAPRTCS database [6], we find that the
outcome of dialysis initiated in the neonatal period (<1 month)
is comparable to that of dialysis in children < 2 years age.
Fig. 1 Kaplan–Meier graphs of
overall rates of survival (strati-
fied by age groups and decade
during which renal replacement
therapy began) among children
and adolescents in Australia and
New Zealand from 1965 to
2005. All patients were followed
until death or the end of follow-
up at 31 December 2005. The
number of patients at risk at
each time point is shown below
each graph. We are grateful to
Drs. Stephen McDonald and
Jonathan Craig for providing
this figure from the ANZDATA
Registry
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amongst different centres, reflecting the varying opinions
amongst nephrologists towards offering RRT to the very
young or those with co-morbidity [7]: the under 5-year-olds
made up 22.9% of the overall cohort of paediatric dialysis
patients in the NAPRTCS report [2] and 9.3% in the
ANZDATA Registry [3]. In our study [8] of 98 children on
long-term dialysis since 1984, 21 were < 1 year of age and
54 were < 5 years at initiation of dialysis. The overall rate
of patient survival was 83%. The mortality rate was 2.7-
times greater in children who required renal replacement
therapy under the age of 5 years [8]. The condition of the
anuric infant is particularly difficult to manage, and anuria
has been discussed as an important risk factor in some
studies [9].
Paediatric dialysis carries a significantly lower mortality
rate than for older age groups on dialysis. The USRDS data
for2006reportamortalityrateforpaediatricdialysispatients
that is 25% that for adults on dialysis. Even young adults
aged 20–44 years have a significantly higher mortality rate
than children (ages 0–19 years), with 5-year and 10-year
adjusted mortality rates of 68.1 vs 60.7 and 52.9 vs 31.6,
respectively [1].
Duration of dialysis
In adults the effect of long-term dialysis (vintage) on
mortality risk is complex and influenced by co-morbidities
and treatment factors. When adjusted for these factors,
vintage is associated with increased mortality rate, although
the rate has been reported to decrease after 8 years on
dialysis, presumably due to early deaths of high-risk
patients [1]. In contrast, the UK Renal Registry reports
that the risk of death does not differ significantly with
increasing length of time on dialysis except in those aged
>65 years after 5–6 years on dialysis [10]. Although
dialysis vintage is considerably shorter in children than in
adults, cardiovascular morbidity has been clearly associated
with the length of time on dialysis [11].
Modality of dialysis
The Italian Registry data report on the survival of 458
children aged less than 15 years who started long-term
dialysis [295 on continuous peritoneal dialysis (CPD)/163
on haemodialysis (HD)] with no preceding RRT from
1989–2000 [12]. Children less than 5 years old were almost
exclusively managed with CPD, and such children had a
poorer 5-year survival rate than children aged 5–15 years
on either CPD or HD, for whom survival rates were not
significantly different. This confirms the findings of Wong
et al., in 2002, who used USRDS data and found no
survival difference between dialysis modalities in children
[13]. However, these data must be interpreted with caution,
as, although some patients will elect HD as their primary
choice of dialysis, it is often only offered when complica-
tions of peritoneal dialysis (PD) occur [2, 10], and, thus,
children on HD may be older, have greater co-morbidity
and a longer dialysis vintage than those on PD, making
comparisons between the groups difficult.
Co-morbidity
In recent years, patients with non-renal co-morbidity, such
as multi-system involvement from inherited disorders,
prematurity or CKD following overwhelming infection
with multi-organ damage, increasingly have been offered
renal replacement therapy. The importance of both renal co-
morbidity, i.e. anuria, and non-renal co-morbidity, including
pulmonary hypoplasia and severe developmental delay as
significant risk factors for increased mortality in infants and
young children, has been identified by analysis of
NAPRTCS data [9] and in smaller studies [14–16]. The
Italian multicentre study also reported a higher proportion
of deaths in the presence of non-renal disease [12].
Our data on the long-term outcome of dialysis have
shown that 30 children out of a cohort of 98 children on
chronic dialysis had significant non-renal co-morbidity,
including neuro-developmental delay, syndromes with
multi-system involvement, congenital cardiac disease,
malignancy and inherited metabolic disorders [8]. Of the
17 deaths in the study group, 76% were of those with
associated co-morbidity, a 7.5-times greater risk of death in
this group [8].
Primary disease
The USRDS cites primary diagnosis as an independent
determinant of mortality for children on dialysis, with those
with glomerulonephritis and hereditary or congenital
disease having a greater 5-year survival than those with
secondary glomerulonephritis or vasculitis [1]. The poor
transplant outcome associated with abnormal bladder
function may be improved by prior augmentation cysto-
plasty, but there is, as yet, no data on the possible effects
this may have on potential long-term PD [17].
As the age at initiation of dialysis and the presence of
both renal and non-renal co-morbidity are unavoidable risk
factors, it is essential that those caring for children on
dialysis are aware of the potentially modifiable factors that
might improve long-term survival and the quality of life for
their patients. Although a successful transplant from a
deceased donor or a live related donor is the goal for all
patients with end-stage renal failure (ESRF) with confirmed
survival benefits, episodes of dialysis or long-term dialysis
may be necessary. It is, therefore, essential that dialysis
Pediatr Nephrol (2009) 24:463–474 465access be preserved, peritoneal membrane function main-
tained, adequate dialysis delivered, metabolic complications
prevented, and adequate nutrition and growth ensured. The
cardiovascular risk factors must be minimized, and every
support offered to ensure continuity of education for the
best long-term outcome.
Treatment factors that may influence outcome
Dialysis access
The initial placement and subsequent conservation of either
vascular or peritoneal access is critical for the young patient
with CKD stage 5 in whom RRT may be a life-long
undertaking. A NAPRTCS study in 2003 of 1,992 incident
dialysis children showed that 70% had been started on PD
and the remaining 30% on HD, with 96% of those < 2 years
old having been started on PD. The NAPRTCS 2006 report
shows that, although HD is being increasingly used as the
incident dialysis modality, approximately 64% of children
continued to start dialysis on PD [2]. In the NAPRTCS
2003 study, although 68% terminated dialysis as they had
received transplants, 20% had changed dialysis modality
over the 6-year study period. The majority of changes from
HD to PD occurred within the first few months, but, in
contrast, the change from PD to HD occurred more slowly
and was mainly attributable to recurrent infections [18].
There was a high rate of PD catheter revision (45%),
mainly due to catheter malfunction. The access in use after
6 months in children on HD was almost exclusively via
percutaneous catheters in those aged less than 6 years, but
57% of those greater than 6 years of age were dialyzed
using an arteriovenous (AV) fistula or graft. HD access
revision rates were very high, with 919 revisions among the
584 initial placements, but 31% were for creation of more
permanent access. Both the National Kidney Foundation–
Dialysis Outcomes Quality Initiative (NKF-DOQI) and the
UK Renal Association now have paediatric clinical practice
guidelines and offer recommendations for optimal dialysis
access and its preservation [19, 20].
Vascular access
Clinical practice guidelines clearly recommend that perma-
nent access as either a native fistula or graft is preferred for
most children on maintenance HD. If central venous
catheters are used (i.e. in small or uncooperative children,
where HD is initiated before a planned live related
transplantation or in patients in whom early transplantation
is anticipated), catheter size should be matched to patient
size to minimize vessel trauma but allow sufficient flow for
adequate HD. External cuffed access should be placed in
the internal jugular vein, with the tip in the right atrium
rather than the subclavian veins where the risk of stenosis is
high. The right side is preferred, as there is decreased risk
of thrombosis and the right side is usually contralateral to
the non-dominant arm, which may eventually be needed for
fistula formation. If possible, in all children with CKD
stages 3–5, the use of the non-dominant arm for venipunc-
ture and lines should be avoided [20, 21]. A study of adults
has shown that HD with any type of venous catheter
compared with a graft or fistula increases the risk of both
all-cause-related mortality and infection-related mortality
[22]. Even in small children, the use of fistulae or grafts is
associated with access survival rates equivalent to those of
adults and with better survival rates than with cuffed
venous catheters [23]. In a 20-year retrospective review of
304 vascular access procedures in children, the median
survival time of arteriovenous fistulae was 3.1 years
compared to 0.6 years for central venous access [24].
Peritoneal dialysis access and preservation of membrane
function
It has become clear that a meticulous approach to PD
catheter insertion by a dedicated team is, perhaps, more
critical than the type of catheter or implantation technique
used with, if possible, planned catheter placement before
RRT becomes essential [20, 25]. However, the recent
NAPRTCS data have shown that the time to the first
episode of peritonitis is longer in children with two cuff
catheters, swan-neck tunnels and for downward pointing
exit sites [2]. Peritoneal membrane function is an indepen-
dent predictor of patient survival, with those with high
transporter status and, therefore, decreased ultrafiltration
capacity demonstrating worse outcomes [26]. In a meta-
analysis Brimble et al. showed an increased mortality risk
of 21.9%, 45.7%, and 77.3% in low-average, high-average
and high transporters, respectively, compared with patients
with low transporter status [27].
As alterations in peritoneal membrane transport appear to
be related to peritonitis episodes rather than the duration of
dialysis, every effort must be directed to reducing peritonitis
rates [28], including intensive training, flush-before-fill
dialysis delivery systems, antibiotic prophylaxis for catheter
insertion, and early treatment of exit site infections.
Although there are no long-term data, the use of biocom-
patible PD solutions, i.e. normal pH, bicarbonate–lactate
buffer, and low glucose concentrations, particularly in
children who are anticipated to have a long wait on PD,
may be advantageous. The use of icodextrin to increase
fluid removal appears to be associated with less
functional deterioration of the peritoneal membrane as
the use of solutions with high glucose concentrations is
avoided [29].
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Haemodialysis
Although the optimum haemodialysis dose has not been
defined in children, the NKF K/DOQI and Renal Associ-
ation guidelines state that children should receive at least
the delivered dialysis dose as recommended for adults, i.e.
either for a urea reduction ratio (URR) > 65% or an
equilibrated Kt/V urea >1.2, delivered thrice weekly [19, 20].
The Hemodialysis (HEMO) Study trial in adults showed no
difference in survival between patients with a mean eKt/Vof
1.16 and those achieving a Kt/Vof 1.53 [30]. These findings
are similar to those in a recent study of 613 adolescents on
HD, in which hospitalization risk was increased with a single
pool Kt/V <1.2 compared to 1.2–1.4 but a spKt/Vof >1.4 did
not improve outcome [31]. However, in a smaller study of 12
children receiving a carefully controlled dietary intake and
with a mean Kt/V of 2, URR 84.7% catch-up growth was
demonstrated [32]. Increasing the frequency of HD sessions
was shown to improve appetite significantly and to increase
growth velocity in a recent small study of children and may
lead to re-evaluation of dialysis adequacy in children [33].
Peritoneal dialysis
Current clinical opinion supports the recommendation that
total solute clearance in paediatric patients should meet or
exceed that in the guidelines for adults of a combined urinary
and peritoneal Kt/V urea value per week of 1.8 [19]o r1 . 7
[10] or a creatinine clearance of 50 L/week per 1.73 m
2 body
surface area. In adult anuric patients a minimum peritoneal
Kt/V urea value of 1.7 and an optimal target of 1.8 is
suggested by Lo et al., based on survival data [34]. A
previous interventional study by the same group clearly
demonstrated increased clinical problems, including severe
anaemia in patients with a total Kt/V of < 1.7, but no
difference in survival outcome between patients with a
Kt/V maintained above 2 and those with a value between
1.7 and 2.0, with the difference in Kt/V accounted for by
increasing peritoneal clearance only [35]. The Adequacy of
Peritoneal Dialysis in Mexico (ADEMEX) trial measured
both peritoneal creatinine clearance and urea clearance as
determinants of small-solute clearance and found no
difference in 2-year survival rates between the control
group and an intervention group with significantly greater
clearances after adjusting for factors known to affect
survival [36]. However, the Netherlands Cooperative Study
on the Adequacy of Dialysis (NECOSAD) clearly identified
an increase in the relative risk of death in anuric PD
patients if the Kt/V urea value was < 1.5/week and
creatinine clearance was < 40 L/week per 1.73 m
2 [37].
There are no comparable mortality data for children, but the
Network 1 Clinical Indicators Project reporting on clinical
morbidity in paediatric dialysis patients found that, in a
small group of well-dialysed patients on either HD or PD,
the exceeding of recommended adequacy guidelines did not
influence morbidity [38]. Indeed, in children on PD, a Kt/V
value of > 2.75 was associated with increased albumin
losses, which may have an adverse effect on nutrition and
growth [39].
Residual renal function
Although the above studies have attempted to describe an
optimal dialysis dose with reference to dialysis adequacy, it
is clear from adult studies that residual renal function
contributes significantly to patient survival. The CANADA-
USA (CANUSA) trial [40] was important in defining
adequacy of small-solute clearance, but re-evaluation of
the data identified that residual renal clearances was a more
important factor for survival than was peritoneal clearance
and combined ultrafiltration [41]. This has been confirmed
in adult HD and PD patients in the NECOSAD studies [37],
and it is recommended that the dialysis prescription take
into account residual renal clearances. A smaller study in
children suggests a correlation between renal solute
clearance rather than peritoneal kt/V value and growth [42].
Studies of adults have shown that episodes of volume
depletion, either unintentional or therapeutic, are associated
with increased risk of loss of residual renal function [37,
43]. However, furosemide has been used successfully to
achieve diuresis and improved fluid balance, without
influencing residual renal function [44]. The use of
angiotensin-converting enzyme inhibitors (ACEi) and
angiotensin II receptor blockers in adult PD patients
suggests a positive effect on preserving residual renal
function [45, 46]. Results of the Effect of Strict Blood
Pressure Control and ACE Inhibition on Progression of
CRF in Pediatric Patients (ESCAPE) trial evaluating the
effect of ramipril on estimated glomerular filtration rate
(eGFR) and proteinuria in children with CKD, including a
small cohort of PD patients, are awaited.
Nutrition and growth
The prevention of malnutrition and associated hypoalbumi-
naemia is critical to the improvement of long-term outcome
and the achievement of optimal growth in children on dialysis.
In a recent teaching article for Pediatric Nephrology,R e e sa n d
Shaw discussed at length the importance of nutrition and
growth in CKD patients [47]; however, some pertinent points
regarding the long-term outcome are mentioned here.
Wong et al. found a significant association between
hypoalbuminaemia and mortality in 1,723 patients aged <
18 years starting dialysis, with each −1 g/dl difference in
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higher risk of death, after adjustment for glomerular causes
and other known risk factors [13]. Poor nutritional intake
occurs early in chronic renal failure (CRF), with deteriora-
tion in anthropometric indices as renal function deteriorates
[48]. A low standard deviation score (SDS) for height at the
start of dialysis is associated with an increased risk of
death, as shown by Wong et al. and Furth et al., with a 14%
increased risk of death with each decrease of 1 SDS for
height [49], and a height SDS of < 2.5 associated with a
doubled risk of death [50], respectively. Thus, early
nutritional intervention may be important both for long-
term survival and linear growth.
Although the NAPRTCS registry data show a decrease
in height SDS, for those on dialysis, from −1.64 [standard
error (SE, 0.03)], to −1.71 (0.04) at 1 year and −1.84 (0.05)
at 2 years [2], we have demonstrated that an early and more
intensive approach to feeding maintains or even improves
height SDS [8, 14, 51]. In our experience, 89% of children
that presented before they were 2 years old with CKD
stages 4– 5, who subsequently underwent dialysis, required
enteral feeding. Their mean height SDS improved from
−2.18 (SD 1.44) at 6 months to −1.74 (1.55) at 1 year and
−1.51 (1.38) at 2 years and improved steadily to −0.87
(1.51) at 5 years [51]. None of these children was treated
with growth hormone. However, the use of recombinant
human growth hormone (rhGH) remains controversial;
some studies have shown that a combination of dialysis
under adequacy control and careful attention to nutrition
can promote normal growth [52], while others support the
use of rhGH in selected cases [53].
Psychosocial outcome
Young adults with childhood-onset CKD stage 5, particu-
larly those who have had a longer period of time on
dialysis, are more likely to have cognitive and learning
impairment than is an age-matched population [54].
Bawden et al. performed neuropsychological assessments
in sibling pairs and showed that, although the children with
CKD 5 had mild deficits of IQ and fine motor coordination,
encouragingly, there were no differences in measures of
academic achievement, memory, behaviour or self-esteem
[55]. More recent studies using health-related quality of life
indices have shown that children with CKD have lower
scores than healthy controls, but, surprisingly, children on
dialysis have higher scores than would be expected,
compared to transplant patients [56, 57]. In support of this,
Groothoff et al. have shown that, although survivors of
prolonged dialysis during childhood are twice as likely to
be unemployed than an age-matched population, and taking
into account the unavoidable physical problems, the overall
subjective health perception of these young adults is
surprisingly good [58]. Addressing the emotional, educa-
tional and social needs of children on dialysis by the
provision of psychosocial and teaching support plays a
crucial role in improving well-being and survival outcome,
and must form an integral part of patient care.
Cardiovascular risk factors
With improvements in renal replacement therapy, cardio-
vascular disease is increasingly recognized as a life-limiting
problem in young patients with CKD, giving a 1,000-times
higher risk of cardiovascular death than in the healthy age-
adjusted population [59]. Analysing the USRDS database,
Parekh et al. reported that 311 of the 1,380 (22.5%) deaths
in patients aged 0–30 years who had undergone dialysis
between 1990 and 1996 were from a cardiac cause [60].
Similarly, ANZDATA [3], the Dutch cohort [4], and
German [11] and Polish [61] single-centre studies reported
cardiovascular disease as the single most common cause of
death in their CKD patients. Chavers et al. presented the
largest study on cardiovascular morbidity in children on
dialysis from the Medicare database [62]. In 1,454 incident
paediatric dialysis patients aged 0–19 years, who underwent
dialysis from 1991–1996, 452 (∼31%) developed a cardiac-
related event. Arrhythmias (19.6%), valvular disease
(11.7%), cardiomyopathy (9.6%) and death from cardiac
arrest (3%) were reported. Unlike adults with CKD in
whom coronary artery disease is the leading cause of death,
cardiac arrest is the most commonly reported cause of death
in children [60].
The ‘traditional’ risk factors, such as diabetes and
dyslipidaemia, cannot account for the greatly increased risk
of cardiovascular disease in children with CKD [63]. CKD
presents a host of metabolic, mechanical and inflammatory
damage-inducing agents, such as mineral imbalance [64, 65]
associated with secondary hyperparathyroidism [66, 67],
inflammatory mediators [68, 69], oxidative stress [70, 71],
hyperhomocysteinaemia [72, 73], hypoalbuminaemia [74],
dyslipidaemia [75], anaemia [76] and chronic fluid overload
[77, 78]. These factors, acting individually or in concert,
result in endothelial dysfunction [72, 73, 79], arterial
stiffness [80, 81], and calcification [82], which contribute
to cardiac remodelling with left ventricular hypertrophy
(Fig. 2). In a recent educational feature, Mitsnefes compre-
hensively discussed cardiovascular morbidity in children
with CKD [83], but some salient risk factors are discussed
below.
Fluid overload and hypertension
Using the NAPRTCS database, Mitsnefes et al. have shown
that 57% of children on long-term dialysis have a blood
pressure(BP)abovetheage-,gender-andheight-specific95th
468 Pediatr Nephrol (2009) 24:463–474centile [84]. In 51% of patients the BP was > 95th centile
after 1 year of dialysis, and it had not changed significantly
after the first year [84]. Also, the pulse pressure (= systolic−
diastolic BP), which reflects the arterial wall compliance, has
been shown to be a significant risk factor for cardiovascular
mortality in adults [85].
Chronic volume overload is the most important factor
contributing to uncontrolled hypertension in the dialysis
population [60], with significantly higher BP in HD patients
than in PD patients reported in all series [60, 78, 86–88]. A
single ‘office’ BP may underestimate the true prevalence of
hypertension, and ambulatory BP monitoring is increasingly
used to diagnose and manage hypertension in dialysis
patients [88–90].
Anaemia
The 2001 NAPRTCS annual report showed that 63% of
children on long-term dialysis were anaemic after 6 months of
dialysis, despite routine use of erythropoietin (EPO) [haemo-
globin (Hb) levels < 11 g/dl] [91]. Warady and Ho report a
52% increased risk of death in association with the presence
of anaemia, with cardiopulmonary or infectious diseases
being the most common causes of death [92]. Recent data
from the UK Renal Registry (9th report) support this
observation: 47% of children on dialysis in the UK have an
Hb < 11 g/dl [93]. Recent studies of adults, reporting
increased morbidity associated with Hb levels > 12 g/dl
[94, 95], have led to a recent revision of the K/DOQI
guidelines that now recommend that Hb levels be maintained
a t>1 1g / d la n d<1 3g / d l[ 96].
Long-standing exposure to the above risk factors leads to
abnormalleftventricular(LV)remodelling,andleftventricular
h y p e r t r o p h y( L V H )h a sb e e nr e p o r t e di n3 0 –80% of children
on dialysis [77, 97–99], with a higher incidence in HD
patients than in PD patients [98]. Two distinct patterns of LV
remodelling are seen in CKD patients: concentric LVH,
resulting from pressure overload, as seen with hypertension
[83, 100], and eccentric LVH that is related to volume
overload, sodium retention and anaemia [83]. LVH leads to a
decreased coronary reserve and arrhythmias [101], which, in
turn, are responsible for a disturbing 1,000-fold increase in
cardiovascular mortality in CKD stage 5 patients [59].
Vascular calcification
Calcification of the arterial media or Monckeberg’s sclero-
sis develops early in the course of CKD [102]. Studies of
children with stages 2–4 CKD and on dialysis have shown
that increased intima–media thickness of the carotid artery
[61, 67, 103] (a measure of structural changes in the vessel
wall), increased pulse wave velocity [67, 104, 105]( a
measure of stiffness or loss of compliance of the vessel) and
presence of coronary and valvular calcification on CT scan
[67, 82, 106] are present as early as the first decade of life.
Secondary hyperparathyroidism, with the associated in-
crease in calcium and phosphate levels [64], and renal bone
disease [107], as well as its treatment with calcium-based
phosphate binders [61, 108] and vitamin D [61, 67, 103],
have been implicated as major cardiovascular risk factors.
Studies of adults have shown that ∼65% have evidence
of calcification even before starting dialysis, using calcium-
Fig. 2 Cardiovascular changes,
underlying risk factors, investi-
gations for assessment and the
clinical outcomes in patients
with CKD, ECHO Echocardio-
gram, FMD Flow mediated
dilatation, IMT Intima media
thickness, PWV Pulse wave
velocity, EBCT Electron Beam
Computed Tomography, MS-CT
Multi-Slice Computed
Tomography
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[109]. Vascular calcification is accelerated on dialysis [11,
61, 103, 104, 106, 108]: worsening hyperparathyroidism
and renal bone disease [63, 107], the presence of ‘damage-
inducing’ inflammatory mediators, oxidative stress and
advanced glycation end-products [68, 69], coupled with a
loss of the naturally occurring inhibitors of calcification
(such as fetuin-A) [110], all play a role in accelerating
vascular calcification. The time on dialysis is a strong
independent predictor of vascular damage and calcification.
Dyslipidaemia
Abnormal lipid profiles are common in the childhood PD
population but have not been extensively studied. Querfeld et
al. reported hypertriglyceridaemia and hypercholesterolaemia
in 69% and 90%, respectively, of children at the start of PD
[75], with no significant change in the lipid profile during
2 years of dialysis. In a population of young PD patients,
Scolnik and Balfe have shown that average serum cholesterol
and triglyceride levels were 27% and 122% higher than the
age-related normal levels [111]. Also, peritoneal losses of the
low molecular weight lipoproteins results in lower levels of
the protective high-density lipoproteins (HDLs) [75, 112]. In a
similarstudyofadultsthetriglyceride,butnotcholesterol,levels
at initiation of dialysis were strong predictors of survival [113].
Summary
In summary, although dialysis in children carries an increased
mortality rate, meticulous care to reduce modifiable risk
factors is important in this group, who have a lifetime of renal
replacement ahead of them.
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Questions
(Answers appear after the reference list)
1. Which one of the following statements regarding
residual renal function (RRF) is true:
A. Once a patient is on dialysis there is no reason to
try and preserve RRF
B. Maintenance of RRF is of importance only for
patients on peritoneal dialysis and not for those on
haemodialysis
C. Angiotensin-converting enzyme inhibitors (ACEi)
have a significant benefit in preserving RRF com-
pared to calcium channel blockers for an equivalent
blood pressure control effect
D. Use of icodextrin allows better preservation of RRF
E. The use of diuretics in peritoneal dialysis patients
is associated with an improvement in the RRF
2. Which one of the following statements regarding
cardiovascular disease (CVD) in children with chronic
kidney disease is false:
A. An elevated level of C-reactive protein (CRP) is a
risk factor for CVD
B. Children with CKD develop CVD because of a
higher prevalence of traditional risk factors such as
diabetes and dyslipidaemia
C. Low serum albumin levels influence cardiovascu-
lar outcome
D. CVD is the single most common cause of death in
young dialysis patients
E. Patientswith CKD can develop vascular calcification
even without the use of calcium-based phosphate
binders or Vitamin D treatment
3. An 18-year-old boy with posterior urethral valves has
had two failed renal transplants and been on continuous
cyclic peritoneal dialysis (CCPD) for ∼6 years. He has
been anuric for the past 4 years. Over the past 6 months
he has developed gradual-onset oedema and reduced
ultrafiltration volume, although the catheter appears to
work well. Which one of the following investigations
or treatment options is not appropriate:
A. Change to a bicarbonate-buffered dialysate in order
to preserve the peritoneal membrane function
B. Use icodextrin for a daytime dwell
C. Start therapy with an angiotensin-converting en-
zyme inhibitor (ACEi) in order to preserve residual
renal function
D. Perform an abdominal CT scan with enteral
contrast agent
E. Perform a 3.86% dextrose dwell time and obtain a
4 h drain volume and measure serum and dialysate
sodium, glucose and creatinine at 0 h, 1 h, 2 h and
4h
4. For the patient described in the above question, which
one of the following statements is most likely when this
patient is aged 30 years:
A. He has developed type 1 diabetes
B. He has had a myocardial infarction
C. He is still on peritoneal dialysis
D. He is in full-time employment
E. He has two children
470 Pediatr Nephrol (2009) 24:463–4745. A4-week-oldtermbabywithposteriorurethralvalvesand
bilateral dysplastic kidneys has a maximum creatinine
concentration of 400 μmol/l (4.5 mg/dl) at 2 weeks of age
and is started on peritoneal dialysis. Which of the
followingstatements suggests a poor long-termprognosis:
A. He has microcephaly
B. His systolic blood pressure is 100 mmHg
C. A postnatal renal ultrasound scan shows kidney sizes
of 6 cm and 8 cm (50th centile for age and height =
5 cm), with multiple small cysts
D. His mother has grade 3 vesicoureteric reflux
E. He develops peritonitis within 1 week of commenc-
ing peritoneal dialysis
6. A 14-year-old boy presents to his local accident and
emergency (A&E) unit with vomiting and lethargy and
has a creatinine concentration of 500 μmol/l (5.7 mg/dl).
Which one of the following interventions is likely to
slow the progression to end-stage renal disease:
A. Dietary protein restriction
B. Use of a statin
C. Maintenance of normal blood pressure
D. Maintenance of Hb >13 g/dl
E. Maintenance of a normal fluid allowance
References
1. US Renal data system (2006) USRDS 2006 Annual data report:
atlas of end stage renal disease in the United States. National
Institutes of Health, National Institute of Diabetes and Digestive
and Kidney Diseases, Bethesda, MD
2. North American Pediatric Renal Trials and Collaborative Studies
(2006) NAPRTCS 2006 Annual report: renal transplantation,
dialysis, chronic renal insufficiency
3. McDonald SP, Craig JC (2004) Long-term survival of children
with end-stage renal disease. N Engl J Med 350:2654–2662
4. Groothoff JW, Gruppen MP, Offringa M, Hutten J, Lilien MR,
Van De Kar NJ, Wolff ED, Davin JC, Heymans HS (2002)
Mortality and causes of death of end-stage renal disease in
children: a Dutch cohort study. Kidney Int 61:621–629
5. UNOS (2007) 2002 Annual report of the US scientific registry of
transplant recipients and the organ procurement and transplanta-
tion network: transplant data 1992–2001. United Network for
Organ Sharing, Rockville, MD
6. Carey WA, Talley LI, Sehring SA, Jaskula JM, Mathias RS
(2007) Outcomes of dialysis initiated during the neonatal period
for treatment of end-stage renal disease: a North American
Pediatric Renal Trials and Collaborative Studies special analysis.
Pediatrics 119:e468–e473
7. Geary DF (1998) Attitudes of pediatric nephrologists to manage-
ment of end-stage renal disease in infants. J Pediatr 133:154–156
8. Shroff R, Rees L, Trompeter R, Hutchinson C, Ledermann S
(2006) Long-term outcome of chronic dialysis in children.
Pediatr Nephrol 21:257–264
9. WoodEG,HandM,BriscoeDM,DonaldsonLA,YiuV,HarleyFL,
Warady BA, Ellis EN (2001) Risk factors for mortality in infants
and young children on dialysis. Am J Kidney Dis 37:573–579
10. UK Renal Registry (2006) The ninth annual report 2006.
11. Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U,
Mehls O, Schaefer F (2002) Advanced coronary and carotid
arteriopathy in young adults with childhood-onset chronic renal
failure. Circulation 106:100–105
12. Verrina E, Edefonti A, Gianoglio B, Rinaldi S, Sorino P,
Zacchello G, Lavoratti G, Maringhini S, Pecoraro C, Calevo
MG, Turrini DL, Perfumo F (2004) A multicenter experience on
patient and technique survival in children on chronic dialysis.
Pediatr Nephrol 19:82–90
13. Wong CS, Hingorani S, Gillen DL, Sherrard DJ, Watkins SL,
Brandt JR, Ball A, Stehman-Breen CO (2002) Hypoalbuminemia
and risk of death in pediatric patients with end-stage renal
disease. Kidney Int 61:630–637
14. Ledermann SE, Scanes ME, Fernando ON, Duffy PG, Madden
SJ, Trompeter RS (2000) Long-term outcome of peritoneal
dialysis in infants. J Pediatr 136:24–29
15. Shroff R, Wright E, Ledermann S, Hutchinson C, Rees L (2003)
Chronic hemodialysis in infants and children under 2 years of
age. Pediatr Nephrol 18:378–383
16. Ellis EN, Pearson D, Champion B, Wood EG (1995) Outcome
of infants on chronic peritoneal dialysis. Adv Perit Dial 11:266–
269
17. Taghizadeh AK, Desai D, Ledermann SE, Shroff R, Marks SD,
Koffman G, Duffy PG, Cuckow PM (2007) Renal transplanta-
tion or bladder augmentation first? A comparison of complica-
tions and outcomes in children. BJU Int 100:1365–1370
18. Leonard MB, Donaldson LA, Ho M, Geary DF (2003) A
prospective cohort study of incident maintenance dialysis in
children: an NAPRTC study. Kidney Int 63:744–755
19. NKF-DOQI (2006) NKF-DOQI: Clinical practice guidelines and
clinical practice recommendations for paediatrics 2006 updates:
Haemodialysis adequacy, Peritoneal dialysis adequacy and
vascular access. Available at www.kidney.org/professionals/
kdoqi/guideline
20. Renal Association (2002) Treatment of adults and children with
renal failure: standards and audit measures
21. Fischbach M, Edefonti A, Schroder C, Watson A (2005)
Hemodialysis in children: general practical guidelines. Pediatr
Nephrol 20:1054–1066
22. Pastan S, Soucie JM, McClellan WM (2002) Vascular access and
increased risk of death among hemodialysis patients. Kidney Int
62:620–626
23. Sheth RD, Brandt ML, Brewer ED, Nuchtern JG, Kale AS,
Goldstein SL (2002) Permanent hemodialysis vascular access
survival in children and adolescents with end-stage renal disease.
Kidney Int 62:1864–1869
24. Ramage IJ, Bailie A, Tyerman KS, McColl JH, Pollard SG,
Fitzpatrick MM (2005) Vascular access survival in children and
young adults receiving long-term hemodialysis. Am J Kidney
Dis 45:708–714
25. White CT, Gowrishankar M, Feber J, Yiu V (2006) Clinical
practice guidelines for pediatric peritoneal dialysis. Pediatr
Nephrol 21:1059–1066
26. Rumpsfeld M, McDonald SP, Johnson DW (2006) Higher
peritoneal transport status is associated with higher mortality
and technique failure in the Australian and New Zealand
peritoneal dialysis patient populations. J Am Soc Nephrol
17:271–278
27. Brimble KS, Walker M, Margetts PJ, Kundhal KK, Rabbat CG
(2006) Meta-analysis: peritoneal membrane transport, mortality,
and technique failure in peritoneal dialysis. J Am Soc Nephrol
17:2591–2598
Pediatr Nephrol (2009) 24:463–474 47128. Andreoli SP, Leiser J, Warady BA, Schlichting L, Brewer ED,
Watkins SL (1999) Adverse effect of peritonitis on peritoneal
membrane function in children on dialysis. Pediatr Nephrol
13:1–6
29. Davies SJ, Brown EA, Frandsen NE, Rodrigues AS, Rodriguez-
Carmona A, Vychytil A, Macnamara E, Ekstrand A, Tranaeus A,
Filho JC (2005) Longitudinal membrane function in functionally
anuric patients treated with APD: data from EAPOS on the
effects of glucose and icodextrin prescription. Kidney Int
67:1609–1615
30. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T,
Kusek JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer
JT, Levey AS, Levin NW, Milford E, Ornt DB, Rocco MV,
Schulman G, Schwab SJ, Teehan BP, Toto R (2002) Effect of
dialysis dose and membrane flux in maintenance hemodialysis.
N Engl J Med 347:2010–2019
31. Gorman G, Furth S, Hwang W, Parekh R, Astor B, Fivush B,
Frankenfield D, Neu A (2006) Clinical outcomes and dialysis
adequacy in adolescent hemodialysis patients. Am J Kidney Dis
47:285–293
32. Tom A, McCauley L, Bell L, Rodd C, Espinosa P, Yu G, Yu J,
Girardin C, Sharma A (1999) Growth during maintenance
hemodialysis: impact of enhanced nutrition and clearance. J
Pediatr 134:464–471
33. Fischbach M, Terzic J, Menouer S, Dheu C, Soskin S,
Helmstetter A, Burger MC (2006) Intensified and daily
hemodialysis in children might improve statural growth. Pediatr
Nephrol 21:1746–1752
34. Lo WK, Lui SL, Chan TM, Li FK, Lam MF, Tse KC, Tang SC,
Choy CB, Lai KN (2005) Minimal and optimal peritoneal Kt/V
targets: results of an anuric peritoneal dialysis patient’s survival
analysis. Kidney Int 67:2032–2038
35. Lo WK, Ho YW, Li CS, Wong KS, Chan TM, Yu AW, Ng FS,
Cheng IK (2003) Effect of Kt/Von survival and clinical outcome
in CAPD patients in a randomized prospective study. Kidney Int
64:649–656
36. Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A,
Moran J, Mujais S (2002) Effects of increased peritoneal
clearances on mortality rates in peritoneal dialysis: ADEMEX,
a prospective, randomized, controlled trial. J Am Soc Nephrol
13:1307–1320
37. Jansen MA, Termorshuizen F, Korevaar JC, Dekker FW,
Boeschoten E, Krediet RT (2005) Predictors of survival in
anuric peritoneal dialysis patients. Kidney Int 68:1199–1205
38. Brem AS, Lambert C, Hill C, Kitsen J, Shemin DG (2001) Clinical
morbidity in pediatric dialysis patients: data from the Network 1
Clinical Indicators Project. Pediatr Nephrol 16:854–857
39. BremAS,LambertC,HillC,KitsenJ,SheminDG(2000)Outcome
data on pediatric dialysis patients from the end-stage renal disease
clinical indicators project. Am J Kidney Dis 36:310–317
40. Canada-USA (CANUSA) Peritoneal DialysisStudy Group(1996)
Adequacy of dialysis and nutrition in continuous peritoneal
dialysis: association with clinical outcomes. J Am Soc Nephrol
7:198–207
41. Bargman JM, Thorpe KE, Churchill DN (2001) Relative
contribution of residual renal function and peritoneal clearance
to adequacy of dialysis: a reanalysis of the CANUSA study. J
Am Soc Nephrol 12:2158–2162
42. Chadha V, Blowey DL, Warady BA (2001) Is growth a valid
outcome measure of dialysis clearance in children undergoing
peritoneal dialysis? Perit Dial Int 21 [Suppl 3]:S179–S184
43. Konings CJ, Kooman JP, Gladziwa U, van der Sande FM,
Leunissen KM (2005) A decline in residual glomerular filtration
during the use of icodextrin may be due to underhydration.
Kidney Int 67:1190–1191
44. Medcalf JF, Harris KP, Walls J (2001) Role of diuretics in the
preservation of residual renal function in patients on continuous
ambulatory peritoneal dialysis. Kidney Int 59:1128–1133
45. Li PK, Chow KM, Wong TY, Leung CB, Szeto CC (2003)
Effects of an angiotensin-converting enzyme inhibitor on
residual renal function in patients receiving peritoneal dialysis.
A randomized, controlled study. Ann Intern Med 139:105–112
46. Suzuki H, Kanno Y, Sugahara S, Okada H, Nakamoto H (2004)
Effects of an angiotensin II receptor blocker, valsartan, on
residual renal function in patients on CAPD. Am J Kidney Dis
43:1056–1064
47. Rees L, Shaw V (2007) Nutrition in children with CRF and on
dialysis. Pediatr Nephrol 22:1689–1702
48. Norman LJ, Coleman JE, Macdonald IA, Tomsett AM, Watson
AR (2000) Nutrition and growth in relation to severity of renal
disease in children. Pediatr Nephrol 15:259–265
49. Wong CS, Gipson DS, Gillen DL, Emerson S, Koepsell T,
Sherrard DJ, Watkins SL, Stehman-Breen C (2000) Anthropo-
metric measures and risk of death in children with end-stage
renal disease. Am J Kidney Dis 36:811–819
50. Furth SL, Stablein D, Fine RN, Powe NR, Fivush BA (2002)
Adverse clinical outcomes associated with short stature at
dialysis initiation: a report of the North American Pediatric
Renal Transplant Cooperative Study. Pediatrics 109:909–913
51. Kari JA, Gonzalez C, Ledermann SE, Shaw V, Rees L (2000)
Outcome and growth of infants with severe chronic renal failure.
Kidney Int 57:1681–1687
52. Holtta T, Ronnholm K, Jalanko H, Holmberg C (2000) Clinical
outcome of pediatric patients on peritoneal dialysis under
adequacy control. Pediatr Nephrol 14:889–897
53. Seikaly MG, Salhab N, Warady BA, Stablein D (2007) Use of
rhGH in children with chronic kidney disease: lessons from
NAPRTCS. Pediatr Nephrol 22:1195–1204
54. Groothoff JW, Grootenhuis M, Dommerholt A, Gruppen MP,
Offringa M, Heymans HS (2002) Impaired cognition and
schooling in adults with end stage renal disease since childhood.
Arch Dis Child 87:380–385
55. Bawden HN, Acott P, Carter J, Lirenman D, MacDonald GW,
McAllister M, McDonnell MC, Shea S, Crocker J (2004)
Neuropsychological functioning in end-stage renal disease. Arch
Dis Child 89:644–647
56. Goldstein SL, Graham N, Burwinkle T, Warady B, Farrah R,
Varni JW (2006) Health-related quality of life in pediatric
patients with ESRD. Pediatr Nephrol 21:846–850
57. McKenna AM, Keating LE, Vigneux A, Stevens S, Williams A,
Geary DF (2006) Quality of life in children with chronic kidney
disease—patient and caregiver assessments. Nephrol Dial Trans-
plant 21:1899–1905
58. Groothoff JW, Grootenhuis MA, Offringa M, Stronks K, Hutten
GJ, Heymans HS (2005) Social consequences in adult life of
end-stage renal disease in childhood. J Pediatr 146:512–517
59. Foley RN, Parfrey PS, Sarnak MJ (1998) Clinical epidemiology
of cardiovascular disease in chronic renal disease. Am J Kidney
Dis 32:S112–S119
60. Parekh RS, Carroll CE, Wolfe RA, Port FK (2002) Cardiovas-
cular mortality in children and young adults with end-stage
kidney disease. J Pediatr 141:191–197
61. Litwin M, Wuhl E, Jourdan C, Trelewicz J, Niemirska A, Fahr
K, Jobs K, Grenda R, Wawer ZT, Rajszys P, Troger J, Mehls O,
Schaefer F (2005) Altered morphologic properties of large
arteries in children with chronic renal failure and after renal
transplantation. J Am Soc Nephrol 16:1494–1500
62. Chavers BM, Li S, Collins AJ, Herzog CA (2002) Cardiovas-
cular disease in pediatric chronic dialysis patients. Kidney Int
62:648–653
472 Pediatr Nephrol (2009) 24:463–47463. Goldsmith D, Ritz E, Covic A (2004) Vascular calcification: a
stiff challenge for the nephrologist: does preventing bone disease
cause arterial disease? Kidney Int 66:1315–1333
64. Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998)
Association of serum phosphorus and calcium × phosphate
product with mortality risk in chronic hemodialysis patients: a
national study. Am J Kidney Dis 31:607–617
65. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG,
Chertow GM (2004) Mineral metabolism, mortality, and morbidity
in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218
66. Rostand SG, Drueke TB (1999) Parathyroid hormone, vitamin
D, and cardiovascular disease in chronic renal failure. Kidney Int
56:383–392
67. Shroff RC, Donald AE, Hiorns MP, Watson A, Feather S,
Milford D, Ellins EA, Storry C, Ridout D, Deanfield J, Rees L
(2007) Mineral metabolism and vascular damage in children on
dialysis. J Am Soc Nephrol 18:2996–3003
68. Shanahan CM (2006) Vascular calcification—a matter of damage
limitation? Nephrol Dial Transplant 21:1166–1169
69. Shroff RC, Shanahan CM (2007) The vascular biology of
calcification. Semin Dial 20:103–109
70. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM (2002) The
elephant in uremia: oxidant stress as a unifying concept of
cardiovascular disease in uremia. Kidney Int 62:1524–1538
71. Nikolov I, Joki N, Drueke T, Massy Z (2006) Beyond
phosphate—role of uraemic toxins in cardiovascular calcifica-
tion. Nephrol Dial Transplant 21:3354–3357
72. Bennett-Richards K, Kattenhorn M, Donald A, Oakley G,
Varghese Z, Rees L, Deanfield JE (2002) Does oral folic acid
lower total homocysteine levels and improve endothelial
function in children with chronic renal failure? Circulation
105:1810–1815
73. Bennett-Richards KJ, Kattenhorn M, Donald AE, Oakley GR,
Varghese Z, Bruckdorfer KR, Deanfield JE, Rees L (2002) Oral
L-arginine does not improve endothelial dysfunction in children
with chronic renal failure. Kidney Int 62:1372–1378
74. Sarafidis PA, Bakris GL (2006) Microalbuminuria and chronic
kidney disease as risk factors for cardiovascular disease. Nephrol
Dial Transplant 21:2366–2374
75. Querfeld U, Salusky IB, Nelson P, Foley J, Fine RN (1988)
Hyperlipidemia in pediatric patients undergoing peritoneal
dialysis. Pediatr Nephrol 2:447–452
76. Mitsnefes MM (2005) Cardiovascular morbidity and mortality in
children with chronic kidney disease in North America: lessons
from the USRDS and NAPRTCS databases. Perit Dial Int 25
[Suppl 3]:S120–S122
77. Mitsnefes MM (2005) Cardiovascular disease in children with
chronic kidney disease. Adv Chronic Kidney Dis 12:397–405
78. Mitsnefes MM (2006) Hypertension in children and adolescents.
Pediatr Clin North Am 53:493–512, viii
79. Kari JA, Donald AE, Vallance DT, Bruckdorfer KR, Leone A,
Mullen MJ, Bunce T, Dorado B, Deanfield JE, Rees L (1997)
Physiology and biochemistry of endothelial function in children
with chronic renal failure. Kidney Int 52:468–472
80. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B,
Adda H (2003) Arterial media calcification in end-stage renal
disease: impact on all-cause and cardiovascular mortality.
Nephrol Dial Transplant 18:1731–1740
81. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME,
London GM (1999) Impact of aortic stiffness on survival in end-
stage renal disease. Circulation 99:2434–2439
82. Goodman WG, London G, Amann K, Block GA, Giachelli C,
Hruska KA, Ketteler M, Levin A, Massy Z, McCarron DA,
Raggi P, Shanahan CM, Yorioka N (2004) Vascular calcification
in chronic kidney disease. Am J Kidney Dis 43:572–579
83. Mitsnefes MM (2008) Cardiovascular complications of pediatric
chronic kidney disease. Pediatr Nephrol 23:27–39
84. Mitsnefes M, Stablein D (2005) Hypertension in pediatric
patients on long-term dialysis: a report of the North American
Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am
J Kidney Dis 45:309–315
85. Klassen PS, Lowrie EG, Reddan DN, DeLong ER, Coladonato
JA, Szczech LA, Lazarus JM, Owen WF Jr (2002) Association
between pulse pressure and mortality in patients undergoing
maintenance hemodialysis. JAMA 287:1548–1555
86. Lerner GR, Warady BA, Sullivan EK, Alexander SR (1999)
Chronic dialysis in children and adolescents. The 1996 annual
report of the North American Pediatric Renal Transplant
Cooperative Study. Pediatr Nephrol 13:404–417
87. Leypoldt JK, Cheung AK, Delmez JA, Gassman JJ, Levin NW,
Lewis JA, Lewis JL, Rocco MV (2002) Relationship between
volume status and blood pressure during chronic hemodialysis.
Kidney Int 61:266–275
88. Lingens N, Soergel M, Loirat C, Busch C, Lemmer B, Scharer K
(1995) Ambulatory blood pressure monitoring in paediatric
patients treated by regular haemodialysis and peritoneal dialysis.
Pediatr Nephrol 9:167–172
89. Mitsnefes MM, Kimball TR, Daniels SR (2003) Office and
ambulatory blood pressure elevation in children with chronic
renal failure. Pediatr Nephrol 18:145–149
90. Sorof JM, Brewer ED, Portman RJ (1999) Ambulatory blood
pressure monitoring and interdialytic weight gain in children
receiving chronic hemodialysis. Am J Kidney Dis 33:667–674
91. Neu AM, Ho PL, McDonald RA, Warady BA (2002) Chronic
dialysis in children and adolescents. The 2001 NAPRTCS
Annual Report. Pediatr Nephrol 17:656–663
92. Warady BA, Ho M (2003) Morbidity and mortality in children
with anemia at initiation of dialysis. Pediatr Nephrol 18:
1055–1062
93. Verrier-Jones K, Reid C, Evans J, Webb N, Gilbert R, Lewis M
(2006) Aspects of Anaemia Management in Children with
Established Renal Failure. UK Renal Registry. The Nineth
Annual Report London: Royal College of Physicians and the
Renal Association, pp 249–252
94. Levin A (2007) The treatment of anemia in chronic kidney
disease: understandings in 2006. Curr Opin Nephrol Hypertens
16:267–271
95. Levin A (2007) Understanding recent haemoglobin trials in
CKD: methods and lesson learned from CREATE and CHOIR.
Nephrol Dial Transplant 22:309–312
96. NKF-DOQI (2006) NKF-DOQI: Clinical practice recommenda-
tions for anaemia management in pediatric patients
97. Mitsnefes MM, Daniels SR, Schwartz SM, Khoury P, Strife CF
(2001) Changes in left ventricular mass in children and
adolescents during chronic dialysis. Pediatr Nephrol 16:318–323
98. Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury
P, Strife CF (2000) Severe left ventricular hypertrophy in
pediatric dialysis: prevalence and predictors. Pediatr Nephrol
14:898–902
99. Morris KP, Skinner JR, Wren C, Hunter S, Coulthard MG (1993)
Cardiac abnormalities in end stage renal failure and anaemia.
Arch Dis Child 68:637–643
100. Ulinski T, Genty J, Viau C, Tillous-Borde I, Deschenes G (2006)
Reduction of left ventricular hypertrophy in children undergoing
hemodialysis. Pediatr Nephrol 21:1171–1178
101. Paoletti E, Specchia C, Di Maio G, Bellino D, Damasio B,
Cassottana P, Cannella G (2004) The worsening of left
ventricular hypertrophy is the strongest predictor of sudden
cardiac death in haemodialysis patients: a 10 year survey.
Nephrol Dial Transplant 19:1829–1834
Pediatr Nephrol (2009) 24:463–474 473102. Qunibi WY (2007) Cardiovascular calcification in nondialyzed
patients with chronic kidney disease. Semin Dial 20:134–138
103. Mitsnefes MM, Kimball TR, Kartal J, Witt SA, Glascock BJ,
Khoury PR, Daniels SR (2005) Cardiac and vascular
adaptation in pediatric patients with chronic kidney disease:
role of calcium-phosphorus metabolism. J Am Soc Nephrol
16:2796–2803
104. Groothoff JW, Gruppen MP, Offringa M, de Groot E, Stok W, Bos
WJ, Davin JC, Lilien MR,Van deKarNC,Wolff ED,Heymans HS
(2002) Increased arterial stiffness in young adults with end-stage
renal disease since childhood. J Am Soc Nephrol 13:2953–2961
105. Covic A, Mardare N, Gusbeth-Tatomir P, Brumaru O, Gavrilovici
C, Munteanu M, Prisada O, Goldsmith DJ (2006) Increased arterial
stiffness in children on haemodialysis. Nephrol Dial Transplant
21:729–735
106. Civilibal M, Caliskan S, Adaletli I, Oflaz H, Sever L, Candan C,
CanpolatN,KasapcopurO,KuruogluS,ArisoyN(2006) Coronary
artery calcifications inchildren with end-stage renal disease.Pediatr
Nephrol 21:1426–1433
107. Sanchez CP, Goodman WG, Ramirez JA, Gales B, Belin TR,
Segre GV, Salusky IB (1995) Calcium-regulated parathyroid
hormone secretion in adynamic renal osteodystrophy. Kidney Int
48:838–843
108. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D,
Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky
IB (2000) Coronary-artery calcification in young adults with
end-stage renal disease who are undergoing dialysis. N Engl J
Med 342:1478–1483
109. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J,
Dreisbach A, Raggi P (2005) Effects of sevelamer and calcium
on coronary artery calcification in patients new to hemodialysis.
Kidney Int 68:1815–1824
110. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken
AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege
J (2003) Association of low fetuin-A (AHSG) concentrations in
serum with cardiovascular mortality in patients on dialysis: a
cross-sectional study. Lancet 361:827–833
111. Scolnik D, Balfe JW (1993) Initial hypoalbuminemia and
hyperlipidemia persist during chronic peritoneal dialysis in
children. Perit Dial Int 13:136–139
112. Querfeld U, LeBoeuf RC, Salusky IB, Nelson P, Laidlaw S, Fine
RN (1991) Lipoproteins in children treated with continuous
peritoneal dialysis. Pediatr Res 29:155–159
113. Pennisi AJ, Heuser ET, Mickey MR, Lipsey A, Malekzadeh MH,
Fine RN (1976) Hyperlipidemia in pediatric hemodialysis and
renal transplant patients. Associated with coronary artery disease.
Am J Dis Child 130:957–961
ANSWERS
1. C
2. B
3. C
4. B
5. A, E
6. C
474 Pediatr Nephrol (2009) 24:463–474